Isorhamnetin Downregulates MMP2 and MMP9 to Inhibit Development of Rheumatoid Arthritis through SRC/ERK/CREB Pathway
© 2023. The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature..
OBJECTIVE: To investigate the effect of isorhamnetin on the pathology of rheumatoid arthritis (RA).
METHODS: Tumor necrosis factor (TNF)- α -induced fibroblast-like synoviocytes (FLS) was exposed to additional isorhamnetin (10, 20 and 40 µ mol/L). Overexpression vectors for matrix metalloproteinase-2 (MMP2) or MMP9 or SRC were transfected to explore their roles in isorhamnetin-mediated RA-FLS function. RA-FLS viability, migration, and invasion were evaluated. Moreover, a collagen-induced arthritis (CIA) rat model was established. Rats were randomly divided to sham, CIA, low-, medium-, and high-dosage groups using a random number table (n=5 in each group) and administed with normal saline or additional isorhamnetin [2, 10, and 20 mg/(kg·day)] for 4 weeks, respectively. Arthritis index was calculated and synovial tissue inflammation was determined in CIA rats. The levels of MMP2, MMP9, TNF-α, interleukin-6 (IL-6), and IL-1 β, as well as the phosphorylation levels of SRC, extracellular regulated kinase (ERK), and cyclic adenosine monophosphate response element-binding (CREB), were detected in RA-FLS and synovial tissue. Molecular docking was also used to analyze the binding of isorhamnetin to SRC.
RESULTS: In in vitro studies, isorhamnetin inhibited RA-FLS viability, migration and invasion (P<0.05). Isorhamnetin downregulated the levels of MMP2, MMP9, TNF-α, IL-6, and IL-1 β in RA-FLS (P<0.05). The overexpression of either MMP2 or MMP9 reversed isorhamnetin-inhibited RA-FLS migration and invasion, as well as the levels of TNF-α, IL-6, and IL-1 β (P<0.05). Furthermore, isorhamnetin bound to SRC and reduced the phosphorylation of SRC, ERK, and CREB (P<0.05). SRC overexpression reversed the inhibitory effect of isorhamnetin on RA-FLS viability, migration and invasion, as well as the negative regulation of MMP2 and MMP9 (P<0.05). In in vivo studies, isorhamnetin decreased arthritis index scores (P<0.05) and alleviated synovial inflammation. Isorhamnetin reduced the levels of MMP2, MMP9, TNF-α, IL-6, and IL-1 β, as well as the phosphorylation of SRC, ERK, and CREB in synovial tissue (P<0.05). Notably, the inhibitory effect of isorhamnetin was more pronounced at higher concentrations (P<0.05).
CONCLUSION: Isorhamnetin exhibited anti-RA effects through modulating SRC/ERK/CREB and MMP2/MMP9 signaling pathways, suggesting that isorhamnetin may be a potential therapeutic agent for RA.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
---|---|
Enthalten in: |
Chinese journal of integrative medicine - 30(2024), 4 vom: 31. März, Seite 299-310 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Liu, Xiao-Rong [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s11655-023-3753-6 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM367030519 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM367030519 | ||
003 | DE-627 | ||
005 | 20240325234628.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240114s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s11655-023-3753-6 |2 doi | |
028 | 5 | 2 | |a pubmed24n1346.xml |
035 | |a (DE-627)NLM367030519 | ||
035 | |a (NLM)38212502 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Liu, Xiao-Rong |e verfasserin |4 aut | |
245 | 1 | 0 | |a Isorhamnetin Downregulates MMP2 and MMP9 to Inhibit Development of Rheumatoid Arthritis through SRC/ERK/CREB Pathway |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.03.2024 | ||
500 | |a Date Revised 25.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature. | ||
520 | |a OBJECTIVE: To investigate the effect of isorhamnetin on the pathology of rheumatoid arthritis (RA) | ||
520 | |a METHODS: Tumor necrosis factor (TNF)- α -induced fibroblast-like synoviocytes (FLS) was exposed to additional isorhamnetin (10, 20 and 40 µ mol/L). Overexpression vectors for matrix metalloproteinase-2 (MMP2) or MMP9 or SRC were transfected to explore their roles in isorhamnetin-mediated RA-FLS function. RA-FLS viability, migration, and invasion were evaluated. Moreover, a collagen-induced arthritis (CIA) rat model was established. Rats were randomly divided to sham, CIA, low-, medium-, and high-dosage groups using a random number table (n=5 in each group) and administed with normal saline or additional isorhamnetin [2, 10, and 20 mg/(kg·day)] for 4 weeks, respectively. Arthritis index was calculated and synovial tissue inflammation was determined in CIA rats. The levels of MMP2, MMP9, TNF-α, interleukin-6 (IL-6), and IL-1 β, as well as the phosphorylation levels of SRC, extracellular regulated kinase (ERK), and cyclic adenosine monophosphate response element-binding (CREB), were detected in RA-FLS and synovial tissue. Molecular docking was also used to analyze the binding of isorhamnetin to SRC | ||
520 | |a RESULTS: In in vitro studies, isorhamnetin inhibited RA-FLS viability, migration and invasion (P<0.05). Isorhamnetin downregulated the levels of MMP2, MMP9, TNF-α, IL-6, and IL-1 β in RA-FLS (P<0.05). The overexpression of either MMP2 or MMP9 reversed isorhamnetin-inhibited RA-FLS migration and invasion, as well as the levels of TNF-α, IL-6, and IL-1 β (P<0.05). Furthermore, isorhamnetin bound to SRC and reduced the phosphorylation of SRC, ERK, and CREB (P<0.05). SRC overexpression reversed the inhibitory effect of isorhamnetin on RA-FLS viability, migration and invasion, as well as the negative regulation of MMP2 and MMP9 (P<0.05). In in vivo studies, isorhamnetin decreased arthritis index scores (P<0.05) and alleviated synovial inflammation. Isorhamnetin reduced the levels of MMP2, MMP9, TNF-α, IL-6, and IL-1 β, as well as the phosphorylation of SRC, ERK, and CREB in synovial tissue (P<0.05). Notably, the inhibitory effect of isorhamnetin was more pronounced at higher concentrations (P<0.05) | ||
520 | |a CONCLUSION: Isorhamnetin exhibited anti-RA effects through modulating SRC/ERK/CREB and MMP2/MMP9 signaling pathways, suggesting that isorhamnetin may be a potential therapeutic agent for RA | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a SRC/ERK/CREB | |
650 | 4 | |a isorhamnetin | |
650 | 4 | |a matrix metalloproteinase | |
650 | 4 | |a rheumatoid arthritis | |
650 | 7 | |a Matrix Metalloproteinase 2 |2 NLM | |
650 | 7 | |a EC 3.4.24.24 |2 NLM | |
650 | 7 | |a src-Family Kinases |2 NLM | |
650 | 7 | |a EC 2.7.10.2 |2 NLM | |
650 | 7 | |a Interleukin-1beta |2 NLM | |
650 | 7 | |a Interleukin-6 |2 NLM | |
650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
650 | 7 | |a 3-methylquercetin |2 NLM | |
650 | 7 | |a 07X3IB4R4Z |2 NLM | |
650 | 7 | |a Matrix Metalloproteinase 9 |2 NLM | |
650 | 7 | |a EC 3.4.24.35 |2 NLM | |
650 | 7 | |a Quercetin |2 NLM | |
650 | 7 | |a 9IKM0I5T1E |2 NLM | |
700 | 1 | |a Li, Shuo-Fu |e verfasserin |4 aut | |
700 | 1 | |a Mei, Wen-Ya |e verfasserin |4 aut | |
700 | 1 | |a Liu, Xiang-Dan |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Ri-Bao |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Chinese journal of integrative medicine |d 2005 |g 30(2024), 4 vom: 31. März, Seite 299-310 |w (DE-627)NLM156144263 |x 1993-0402 |7 nnns |
773 | 1 | 8 | |g volume:30 |g year:2024 |g number:4 |g day:31 |g month:03 |g pages:299-310 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11655-023-3753-6 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 30 |j 2024 |e 4 |b 31 |c 03 |h 299-310 |